MAFLD identifies patients with significant hepatic fibrosis better than NAFLD-Reference-Cited by-同舟云学术

MAFLD identifies patients with significant hepatic fibrosis better than NAFLD

Published:2020-11-30 Issue:12 Volume:40 Page:3018-3030
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Yamamura Sakura¹^ORCID,Eslam Mohammed²^ORCID,Kawaguchi Takumi¹^ORCID,Tsutsumi Tsubasa¹^ORCID,Nakano Dan¹^ORCID,Yoshinaga Shinobu³,Takahashi Hirokazu⁴^ORCID,Anzai Keizo⁴,George Jacob²,Torimura Takuji¹

Affiliation:

1. Division of Gastroenterology Department of Medicine Kurume University School of Medicine Kurume Japan

2. Storr Liver Centre Westmead Institute for Medical ResearchWestmead Hospital and University of Sydney Sydney NSW Australia

3. Medical Examination Section Medical Examination Part Facilities Public Utility Foundation Saga Prefectural Health Promotion Foundation Saga Japan

4. Division of Metabolism and Endocrinology Faculty of Medicine Saga University Saga Japan

Funder

Japan Agency for Medical Research and Development

Research and Development

Medical Foundation

University of Sydney

Medical Research Council

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14675

Reference35 articles.

1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

2. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

3. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study

4. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

5. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study;Diabetes & Metabolism Journal;2024-09-30

2. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease;Annals of Hepatology;2024-09

3. G-quadruplex forming regions in GCK and TM6SF2 are targets for differential DNA methylation in metabolic disease and hepatocellular carcinoma patients;Scientific Reports;2024-08-30

4. From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction;Metabolism and Target Organ Damage;2024-08-28

5. Proportion and clinical characteristics of metabolic-associated fatty liver disease and associated liver fibrosis in an urban Chinese population;Chinese Medical Journal;2024-08-26